title: Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus: a case-case-control study.
abstract: Linezolid is an important agent for the treatment of infections because of vancomycin-resistant Enterococcus (VRE). This study identified independent predictors for isolation of linezolid-resistant VRE (LZD-R-VRE) and analyzed outcomes associated with linezolid resistance. Immunosuppression, prior surgery, and previous exposure to β-lactam antibiotics were independent predictors for isolation of LZD-R-VRE but not for LZD-susceptible-VRE. Prior exposure to linezolid was not a predictor for isolation of LZD-R-VRE.
authors.affiliation: Division of Infectious Diseases, Wayne State University, Detroit Medical Center, Detroit, MI 48201, USA. fastriver7k@yahoo.co.jp
authors.forename: Kayoko
authors.initials: K
authors.lastname: Hayakawa
authors.forename: Dror
authors.initials: D
authors.lastname: Marchaim
authors.forename: Jason M
authors.initials: JM
authors.lastname: Pogue
authors.forename: Kevin
authors.initials: K
authors.lastname: Ho
authors.forename: Shakila
authors.initials: S
authors.lastname: Parveen
authors.forename: Priyanka
authors.initials: P
authors.lastname: Nanjireddy
authors.forename: Bharath
authors.initials: B
authors.lastname: Sunkara
authors.forename: Manit
authors.initials: M
authors.lastname: Singla
authors.forename: Kavyashri Kodlipet
authors.initials: KK
authors.lastname: Jagadeesh
authors.forename: Judy A
authors.initials: JA
authors.lastname: Moshos
authors.forename: Sarah
authors.initials: S
authors.lastname: Bommarito
authors.forename: Rida
authors.initials: R
authors.lastname: Mroue
authors.forename: Mohamad
authors.initials: M
authors.lastname: Farhat
authors.forename: Tarek
authors.initials: T
authors.lastname: Obeid
authors.forename: Aaisha
authors.initials: A
authors.lastname: Chaudhry
authors.forename: Gayathri
authors.initials: G
authors.lastname: Vadlamudi
authors.forename: Paul R
authors.initials: PR
authors.lastname: Lephart
authors.forename: Emily T
authors.initials: ET
authors.lastname: Martin
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Rybak
authors.forename: Keith S
authors.initials: KS
authors.lastname: Kaye
mesh_terms: D000081:Acetamides / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D024881:Drug Resistance, Bacterial; D016983:Enterococcus / Q000187:drug effects* / Q000302:isolation & purification; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D006801:Humans; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000494:pharmacology / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D000081:Acetamides; D023303:Oxazolidinones; D014640:Vancomycin; D000069349:Linezolid